Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc.이(가) 2026년 9월 3일에 보고한 내용

기업이 직접 제출한 8-K에서 가져왔습니다.

실적 발표 컨퍼런스 콜

Latigo Biotherapeutics, Inc.의 실적 발표 콜 녹취록이 없습니다.

경영진의 발언

“This has been a significant period for Latigo as we completed our upsized initial public offering, published positive onzotrigine abdominoplasty results in moderate-to-severe acute pain in The New England Journal of Medicine, and continued to advance our pipeline of innovative pain programs,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

주가는 어떻게 반응했나

실적 발표는 장 마감 후나 개장 전에 나오므로, 여기서 말하는 변동은 그다음 거래일입니다.

Latigo Biotherapeutics, Inc.은(는) 무엇을 하는 기업인가

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines. Latigo’s drug candidates are designed to rapidly and effectively stop the transmission of pain without the risk of addiction. The Company’s lead product candidate, onzotrigine (previously referred to as LTG-001) is an oral Na v 1.8 ion channel inhibitor intended to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is an oral Na v 1.8 inhibitor being developed for chronic musculoskeletal pain. Additionally, Latigo is advancing research of additional Na v 1.8 inhibitors that can address alternative formulation and delivery approaches as well as other ion channel targets for the treatment of pain. Learn more at latigobio.com or follow us on LinkedIn and X .

발표 자료 말미에 실린 기업 자신의 소개글입니다.